Clinical trial seeks to improve patient treatment for Crohn's disease

Jan 04, 2010

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease. The outcome is expected to lead to a more streamlined treatment path and better disease management for patients. Abbott, the global health care company, has provided a grant to complete research for the REACT (Randomized Evaluation of an Algorithm for Crohn's Treatment) study.

Crohn's disease is a chronic inflammatory disorder that is characterized by symptoms of diarrhea, abdominal pain and gastrointestinal bleeding. It typically effects younger people and can result in serious complications such as bowel obstruction. Although conventional anti-inflammatory treatments such as prednisone improve symptoms, they are associated with important side effects and are only partially effective. Many patients require surgery to treat the disease.

The REACT study will be carried out at 40 gastroenterology practices in Canada and Belgium. The sites will be randomly assigned to treat patients with to either a conventional management strategy featuring gradual escalation of drug therapy or a newer paradigm that features early use of combined with a alpha blocking drug and an anti-metabolite.

"This trial builds on the results of recent studies that suggest use of combined therapy early in the course of treatment yields superior long-term results," says Dr. Brian Feagan, the lead investigator for the study. "We are excited about this project since it is the first large-scale, community-based evaluation of this approach. We expect that patients treated with combination therapy will be more likely to enter remission and rates of hospitalization and health-care utilization will be reduced." Dr. Feagan is the Director of Robarts Clinical Trials and a professor in the Department of Medicine at Western's Schulich School of Medicine & Dentistry.

Explore further: NY and NJ say they will require Ebola quarantines

Provided by University of Western Ontario

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Omega-3's no help for Crohn's sufferers

Apr 08, 2008

An international study led by Dr. Brian Feagan of Robarts Research Institute at The University of Western Ontario in London, Canada has found that omega-3 fatty acids are ineffective for managing Crohn’s disease. The research ...

ECP may be effective in treating Crohn's disease

May 25, 2007

(Washington, DC - May 23, 2007) -- Results from an international multi-center Phase II clinical trial suggest that extracorporeal photopheresis (ECP) may be effective in treating patients with clinically active (OR symptomatic) ...

Recommended for you

NY and NJ say they will require Ebola quarantines

29 minutes ago

The governors of New Jersey and New York on Friday ordered a mandatory, 21-day quarantine for all doctors and other arriving travelers who have had contact with Ebola victims in West Africa.

WHO: Mali case may have infected many people

4 hours ago

The World Health Organization says a toddler who brought Ebola to Mali was bleeding from her nose during her journey on public transport and may have infected many people.

Two US nurses are declared cured of Ebola

5 hours ago

Two American nurses were declared cured of Ebola on Friday, and one was healthy enough to leave the hospital and meet President Barack Obama for a hug.

User comments : 0